ISOLATED HYPERTHERMIC CHEMOPERFUSION OF THE LIVER IN ITS METASTATIC LESIONS
https://doi.org/10.24884/0042-4625-2018-177-1-54-59
Abstract
OBJECTIVE. The aim of the study is to evaluate the clinical efficacy of isolated hyperthermic liver chemoperfusion with melphalan and tumor necrosis factor alpha when it is isolated bilobate metastatic lesion and the ineffectiveness of systemic chemotherapy in patients with colorectal cancer. MATERIAL AND METHODS. The patient K, 67 y. o., with colorectal adenocarcinoma T3N0M1 (hep, 3 type). liver metastases were detected synchronously with the detection of the primary tumor. Resection of the primary tumor was performed at first, then there was systemic chemotherapy (6 FOLFOX and 3 FOLFIRI). The was tumor progression in liver after second-line chemotherapy. Isolated hyperthermic liver chemoperfusion was perfomed after complete vascular exclusion of the liver with parallel circulation to return blood to the system of the superior vena cava from the inferior vena cava and portal vein. hepatic perfusion in heart-lung machine with the chemotherapy drugs (melphalan and tumor necrosis factor alpha) carried out through the gastro-duodenal artery and back flow to the circulation circuit from the retro-hepatic vena cava. RESULTS. Using of the isolated hyperthermic liver chemoperfusion allowed reaching full necrosis of liver metastases that confirmed by histopathology results and CT data of the abdominal cavity in a month after the procedure. CONCLUSION. Isolated hyperthermic liver chemoperfusion with melphalan and tumor necrosis factor alpha is the effective method of regional chemotherapy, which is advisable in patients with unresectable isolated metastatic lesion of the liver and resistible to systemic chemotherapy.
About the Authors
N. A. Maistrenko
S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation, Saint-Petersburg
Russian Federation
Department and Clinic of Faculty Surgery named after S. P. Fedorov
Russian Federation
Department and Clinic of Faculty Surgery named after S. P. Fedorov
A. I. Babich
PC «Medex Clinic Kostroma» Regional State Budgetary Institution of Healthcare «Kostroma oncological dispensary», Kostroma
Russian Federation
Russian Federation
P. N. Romashchenko
S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation, Saint-Petersburg
Russian Federation
Russian Federation
Yu. A. Pobedinceva
PC «Medex Clinic Kostroma» Regional State Budgetary Institution of Healthcare «Kostroma oncological dispensary», Kostroma
Russian Federation
Russian Federation
V. M. Unguryan
PC «Medex Clinic Kostroma» Regional State Budgetary Institution of Healthcare «Kostroma oncological dispensary», Kostroma
Russian Federation
Russian Federation
V. A. Kudlachev
PC «Medex Clinic Kostroma» Regional State Budgetary Institution of Healthcare «Kostroma oncological dispensary», Kostroma
Russian Federation
Russian Federation
T. Yu. Kushtan
S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation, Saint-Petersburg
Russian Federation
Russian Federation
A. I. Strogonov
S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation, Saint-Petersburg
Russian Federation
Russian Federation
References
1. Ausman R. K. Development of atechnique for isolated perfusion of the liver // N. Y. StateJ. Med. 1961. Vol. 61. P. 3393–3397.
2. Aigner K., Walther H., Tonn J. et al. First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary // Recent Results Cancer Res. 1983. Vol.
3. P. 99–102.
4. Alexander H. Jr., Bartlett D., Libutti S. et al. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center // Ann. Surg. Oncol. 2009.Vol. 16. P. 1852–1859. doi: 10.1245/s1043400904829.
5. Alexander H. Jr., Libutti S., Bartlett D. et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy // Cancer. 2002. Vol. 95. P. 730–736. doi: 10.1002/cncr.10686.
6. Alexander H. Jr., Libutti S., Pingpank J. et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecanbased therapy // Ann. Surg. Oncol. 2005.Vol. 12. P. 138–144. doi: 10.1245/aso.2005.05.003).
7. GruberRouh T., Naguib N., Eichler K. et al. Transarterial chemoembolization of unresectable systemic chemotherapyrefractory liver metastases from colorectal cancer : longterm results over a 10year period // Int. J. Cancer. 2013. Vol. 134. P. 1225–1231. doi: 10.1002/ijc.28443.
8. Hafstrцm L., Holmberg S., Naredi P. et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy // Surg. Oncol. 1994. Vol.3. P. 103–108. doi: 10.1016/09607404(94)900051.
9. Leporrier J., Maurel J., Chiche L. et al. A populationbased study of the incidence, management and prognosis of hepatic metastases from colorectal cancer // Br. J. Surg. 2006. Vol. 93. P. 465–474. doi: 10.1002/bjs.5278.
10. Masi G., Vasile E., Loupakis F. et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer : an updated analysis //J. Natl. Cancer. Inst. 2011. Vol. 103. P. 21–30. doi: 10.1093/jnci/djq456.
11. Rothbarth J., Pijl M., Vahrmeijer A. et al. Isolated hepatic perfusion with highdose melphalan for the treatment of colorectal metastasis confined to the liver // Br. J. Surg. 2003. Vol. 90. P. 1391–1397. doi: 10.1002/bjs.4308.
12. Rothenberg M., Cox J., Butts C. et al. Capecitabine plus oxaliplatin (XELOX) versus 5fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as secondline therapy in metastatic colorectal cancer: a randomized phase III noninferiority study // Ann. Oncol. 2008. Vol. 19. P. 1720–1726. doi: 10.1093/annonc/mdn370.
13. Schwemmle K., Link K., Rieck B. Rationale and indications for perfusion in liver tumors : current data // World. J. Surg. 1987. Vol. 11. P. 534–540.
14. Tzeng C., Aloia T. Colorectal liver metastases // J. Gastrointest. Surg. 2013. Vol. 17. P. 195–201. doi: 10.1007/s1160501220223.
15. van Iersel L., Koopman M., van de Velde C. et al. Management of isolated nonresectable liver metastases in colorectal cancer patients : a casecontrol study of isolated hepatic perfusion with melphalan versus systemic chemotherapy // Ann. Oncol. 2010. Vol. 21. P. 1662–1667. doi: 10.1093/annonc/mdp589.
16. World Medical Association (2013). Declaration of Helsinki : Ethical Principles for Medical Research Involving Human Subjects // Jама. 2013. Vol. 20. P. 2191–2194. doi: 10.1001/ jama.2013.281053.
Review
For citations:
Maistrenko N.A., Babich A.I., Romashchenko P.N., Pobedinceva Yu.A., Unguryan V.M., Kudlachev V.A., Kushtan T.Yu., Strogonov A.I. ISOLATED HYPERTHERMIC CHEMOPERFUSION OF THE LIVER IN ITS METASTATIC LESIONS. Grekov's Bulletin of Surgery. 2018;177(1):54-59. (In Russ.) https://doi.org/10.24884/0042-4625-2018-177-1-54-59
Views:
1361
Email this article 